Back to Search
RISHABH SINGH, M.B.B.S.
M.B.B.S.
Internal Medicine Physician
NPI: 1700521507Individual
Specialties, Licenses & Credentials
Clinical Trials (2)
2
Linked Trials
0
Recruiting
2
With Results
Research & Publications (6)
Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis.
PMID 31367468·Int J Retina Vitreous·2019
8-other
A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis.
PMID 26445522·Clin Ophthalmol·2015
8-other
A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis.
PMID 24836866·Br J Ophthalmol·2014
2-rct
Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema.
PMID 22423055·Br J Ophthalmol·2012
8-other
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization.
PMID 12824270·Invest Ophthalmol Vis Sci·2003
7-preclinical
Vascular endothelial growth factor and the regulation of angiogenesis.
PMID 11036931·Recent Prog Horm Res·2000
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 535 BARNHILL DR
INDIANAPOLIS, IN 46202 - Phone
- (317) 948-6942
Quick Facts
- NPI
- 1700521507
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 2
- Publications
- 6
Are you this provider?
Claim Your Profile